➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
Dow
Moodys
Baxter
AstraZeneca

Last Updated: September 20, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,119,148

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,119,148 protect, and when does it expire?

Patent 8,119,148 protects TRILEPTAL and is included in one NDA.

Protection for TRILEPTAL has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-six patent family members in thirty-three countries.

Summary for Patent: 8,119,148
Title:Suspension comprising oxcarbazepine
Abstract: This invention provides a pharmaceutical composition in the form of a suspension comprising oxcarbazepine.
Inventor(s): Sigg; Juergen (Loerrach, DE), Billington; Michael (Riehen, CH)
Assignee: Novartis Pharmaceuticals Corporation (East Hanover, NJ)
Application Number:10/168,248
Patent Claim Types:
see list of patent claims
Composition; Compound; Use;

Drugs Protected by US Patent 8,119,148

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis TRILEPTAL oxcarbazepine SUSPENSION;ORAL 021285-001 May 25, 2001 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,119,148

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9930058.4Dec 20, 1999
PCT Information
PCT FiledDecember 19, 2000PCT Application Number:PCT/EP00/12968
PCT Publication Date:June 28, 2001PCT Publication Number: WO01/45671

International Family Members for US Patent 8,119,148

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 030175   Start Trial
Austria 269694   Start Trial
Australia 2511801   Start Trial
Australia 777619   Start Trial
Belgium 1013706   Start Trial
Belgium 1014502   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
McKesson
Medtronic
Harvard Business School
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.